^
Association details:
| Biomarker: | HER-2 amplification |
|---|---|
| Cancer: | Bladder Cancer |
| Drug: | Enhertu (fam-trastuzumab deruxtecan-nxki) (Topoisomerase I inhibitor, HER2-targeted antibody-drug conjugate) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
5931 / 9 - Characterizing tumor heterogeneity through bulk and single cell analysis of patient derived bladder cancer models
Published date:
03/15/2023
Excerpt:
Preclinical evaluation of HER2-altered PDO/PDXs indicated significantly greater sensitivity to the HER2-directed ADC T-DXd compared to the HER kinase inhibitor neratinib, providing rationale for future clinical trials of HER2 ADCs in bladder cancer patients.
